Dealroom · Jul 2026
Reports a $2.06M NIAAA grant for IND-enabling work on a TERT mRNA therapy for alcoholic hepatitis, following prior regulatory progress and earlier awards.
We extend telomeres to extend the human health span
Company research
Public company, workplace, funding, and market signals
Overview
Mountain View biotech developing transient TERT mRNA therapeutics in proprietary lipid nanoparticles to extend telomeres and reverse cellular aging. Public sources conflict on founding year (2016 vs 2018); using 2018 from the company’s LinkedIn/Y Combinator profile, while older directories list 2016.
Primary product
TERT mRNA lipid nanoparticle therapeutics for telomere extension
Founded
2018
Headquarters
Mountain View, CA 94043, United States
Team size
10-20 employees
Industry
Biotechnology
Sub-industry
Longevity biotech / mRNA therapeutics
Offices
Mountain View, CA 94043, United States
Open Positions
0 jobs at Rejuvenation Technologies Inc.
No open positions
Check back later for new openings